Sansure Biotech(SH:688289) Sou Hu Cai Jing·2025-11-08 19:02Core Viewpoint - Shengxiang Biotechnology Co., Ltd. is actively expanding its investment and product portfolio in the medical device sector, focusing on AI medical applications and innovative diagnostic tools [2][4]. Group 1: Company Financials and Market Position - As of November 7, 2025, Shengxiang Biotechnology's stock closed at 21.75 yuan, down 1.36% from the previous week [1]. - The company's current total market capitalization is 12.602 billion yuan, ranking 23rd out of 126 in the medical device sector and 1536th out of 5166 in the A-share market [1]. Group 2: Recent Announcements - Shengxiang Biotechnology plans to establish a medical industry fund with a target fundraising scale of 1 billion yuan, contributing 370 million yuan, which accounts for 37% of the fund [2][4]. - The fund will focus on investing in AI medical applications and innovative medical technology companies with significant market potential [2]. - The company has recently obtained three product certifications, including two Class III medical device registrations and one EU CE IVDR certification, enhancing its diagnostic capabilities for viral infections [2][4].